Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury

Pediatric Hematology and Oncology

Volumn 27, Issue 1, 2010, Pages 46-52

  Mahadeo, Kris M ^a   Dhall, Girish ^b   Panigrahy, Ashok ^b   Lastra, Carlos ^c   Ettinger, Lawrence J ^d  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^d JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

ALL; Homocysteine; Leukemia; Methotrexate; Neurotoxicity of therapy; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DEXTROMETHORPHAN; DOXORUBICIN; ENOXAPARIN; FOLIC ACID; HOMOCYSTEINE; HYDROCORTISONE; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APHASIA; ARTICLE; BLOOD LEVEL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CHILD; CHROMOSOME TRANSLOCATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ENDOTHELIUM INJURY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEMIPARESIS; HOMOCYSTINURIA; HOMOZYGOSITY; HUMAN; MALE; MENTAL DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; REMISSION; SCHOOL CHILD; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT RESPONSE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CYTARABINE; DAUNORUBICIN; ENDOTHELIUM, VASCULAR; EPILEPSY, TONIC-CLONIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERHOMOCYSTEINEMIA; INJECTIONS, SPINAL; LEUKOENCEPHALOPATHIES; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; REMISSION INDUCTION; SINUS THROMBOSIS, INTRACRANIAL; VINCRISTINE;

EID: 76649098342     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880010903341904     Document Type: Article

References (20)

1. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548-2555.
2. Steinherz PG, Redner A, Steinherz L, et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: the Memorial Sloan- Kettering-New York-II protocol. Cancer. 1993; 72:3120-3130.
3. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975;35:291-305.
4. Silverstein FS, JohnstonMV. Amodel of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities. J Child Neurol. 1986;1:351-357.
5. Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol. 1973;28:96-102.
6. Kay HE, Knapton PJ, O'Sullivan JP, et al. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child. 1972;47:344-354.
7. Krajinovic M, Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood. 2004;103:252-257. (Pubitemid 38029946)
8. Quinn CT, Kamen BA. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med. 1996;44:522-530.
9. Strunk T, Gottschalk S, Goepel W, et al. Subacute leukoencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Med Pediatr Oncol. 2003;40:48-50.
10. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogentetics of antileukemic drug toxicity. Blood. 2007;109:4151-4157.
11. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C°T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003;103:294-299.
12. Turello R, Rentsch K, Di Paolo E, et al. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism. Pediatr Blood Cancer. 2007;50:154-156.
13. Kishi T, Tanaka Y, Ueda K. Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer. 2000;89:925-931.
14. Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol. 1998;16:1505-1511.
15. Quinn CT, Griener JC, Bottiglieri T, et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol. 1997; 15: 2800-2806.
16. Do KQ, Herrling PL, Streit P, Cúenod M. Release of neuroactive substances: homocysteic acid as an endogenous agonist of the NMDA receptor. J Neural Transm. 1988;72:185-190.
17. Quinn CT, Greiner JC, Bottigliri T, Kamen, B. Methotrexate, homocysteine and seizures. J Clin Oncol. 1998; 16: 393-394.
18. Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002; 19:319-327.
19. Lee R, Frenkel EP. Hyperhomocysteinemia and thrombosis. Hematol Oncol Clin North Am. 2003;17: 85-102.
20. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004; 62:451-456